Shiyao Group (01093.HK): Phase I clinical trial data of the new B7-H3 antibody-conjugated drug SYS6043 will be presented in the form of an oral report at the 2026 ASCO Annual Meeting.

Wisdom Finance News APP, Sihuan Pharmaceutical Group (01093.HK) announced that its subsidiary, Sihuan Pharmaceutical Group Juishi Biopharmaceutical Co., Ltd., has presented the Phase I clinical research data of SYS6043 at the 2026 American Society of Clinical Oncology (ASCO) annual meeting in the form of an oral report.